MA-ALAKA’I-TECHNOLOGIES
29.5.2019 23:02:12 CEST | Business Wire | Press release
Today, Alaka’i Technologies unveiled Skai, the world’s first hydrogen fuel cell powered air mobility solution designed to transform the way the world moves. From its sleek, uncluttered design, radically simple and safe electric vertical takeoff and landing (eVTOL) vehicle, to its fuel source - a system that runs entirely on hydrogen fuel cells - Skai is poised to be one of the safest, cleanest and most versatile air mobility solutions introduced to the world.
Skai’s core team members are nationally-recognized aerospace experts, engineers, and veteran pilots who have served in top-level positions at NASA, Raytheon, Beech, Cirrus, DayJet, and the Department of Defense who collaborated on the vision of solving some of the world’s most-pressing global challenges across transportation, energy and the environment. Skai is co-designed by Designworks, the design innovation studio for the BMW Group, to leverage its creative expertise to help shape a world-class vehicle. The result is Skai, stripped away of all unnecessary complexity, waste and possible points of failure, leaving the most essential elements for the craft and optimizing them for the most intuitive experience.
“This remarkably impressive team have come together to build on our collective experience to finally realize our singular, critical vision to launch Skai and transform transportation,” said Brian Morrison, Co-Founder, President and Chief Technology Officer of Alaka’i Technologies. “Skai offers practical, real-life solutions to everything from relieving traffic congestion to delivering supplies during natural disasters. Skai is set to offer affordable, realistic applications in the commercial, private, freight, and personal air mobility markets.”
The heart of Skai, and one of its most revolutionary features, is the use of hydrogen fuel cells, a clean environmental solution from end to end. With the advantage of being 95% reusable and the remaining (99%) recyclable, Skai’s hydrogen fuel cells offer reliable, safe and environmentally clean emission comprised solely of heat and water. This is a stark alternative to traditional fuel and battery sources. Hydrogen fuel cells allow Skai to travel further distances and carry a greater payload.
“Air mobility is a very exciting and fascinating topic,” said Holger Hampf, President of Designworks. “Our focus for this project was to help build a new consumer facing brand from scratch - considering and designing all touchpoints - digital, physical and service. And as a result, delivering an all-encompassing user-centric experience which is purposeful and highly desirable in all aspects.”
Alaka’i Technologies has initiated their test program with the FAA. Pending certification, Skai will create new possibilities in personal mobility for everyone, efficient emergency responses, economical freight distribution, and the utilization of hydrogen fuel cells as a highly reliable, zero-emission power source.
Skai Highlights Include:
- Co-designed by Designworks with inherent quality craftsmanship
- Powered by clean hydrogen fuel cells, with zero emissions
- Range: Up to 4 Hours, ~400 Miles
- Six reliable, quiet, efficient electric motors with designed-in redundancy
- Seats up to five passengers
- Reliable, fault-tolerant architecture for safety and security
- Piloted version launched first, with autonomous versions to follow
- Designed for the ultimate in safety, with an Airframe Parachute
For more information: http://skai.co .
ABOUT ALAKA’I
Alaka’i Technologies is an emerging air mobility design and manufacturing company, headquartered in Hopkinton MA. Founded by Brian Morrison in 2015, Alaka’i Technologies assembled a distinguished executive team with decades of aerospace development, production, executive and airspace integration experience (NASA, Raytheon, Beech Aircraft, McDonnell Douglas, Hughes, DayJet, SATSAir, Cirrus, Metro Aviation, Delta Airlines) and FAA certification experience. Working together since the 1990’s on industry-defining projects such as the NASA AGATE and SATS Programs, they also built and flew the world’s first-ever Fly-By-Light aircraft. Today, the Alaka'i team is engineering proprietary, progressive air mobility solutions to offer point A-to-Anywhere transportation that are clean, simple, safe, and accessible for everyone. Ultimately, transforming transportation through hydrogen-powered mobility.
ABOUT DESIGNWORKS
Designworks is the design innovation studio for the BMW Group. Designworks is ‘the architect of future’ — designing holistic systems that impact and improve the world we live in. Designworks inspires and challenges the companies it works with to be and stay at the forefront of their industries in design, technology and innovation. For 25 years it has been stimulating the BMW Group as well as a select group of companies with ambitious visions for the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005834/en/
Contact:
John Moore Press@alakai.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom